Finland Country Drug Report 2018

Public expenditure

Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments for expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.

The Finnish government approves an annual drug budget that is in line with its drug strategy and action plan. Annual estimates of expenditures are also provided and include both labelled and unlabelled expenditures. The most recent available data on public expenditure in Finland are for 2013. Estimates for more recent years are expected in 2018.

In 2013, total drug-related expenditure represented 0.2 % of gross domestic product, which was approximately EUR 412 000. Of this, the majority was spent on public order and safety, and the remaining budget on social protection and healthcare.

In 2013, total drug-related public expenditure in Finland remained broadly unchanged in real terms (it increased by 1 %) compared with 2012; however, it increased by 2.4 % in nominal terms.


Finland main page

Methodological note: Analysis of trends is based only on those countries providing sufficient data to describe changes over the period specified. The reader should also be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in this report. Caution is therefore required in interpretation, in particular when countries are compared on any single measure. Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.